Pancreatic cancer remains one of the most aggressive and lethal malignancies due to its high chemoresistance. This is majorly attributed to the desmoplastic reaction - a severe fibrotic response that hinders drug delivery, and hypoxia - low oxygen levels in tumours that promote cell survival, stemness, and resistance mechanisms. Researchers are exploring various avenues to overcome these challenges.
1. Targeting Desmoplasia: The thick fibrotic stroma surrounding the tumour cells acts as a physical barrier to drug delivery. Recent strategies include developing drugs that can penetrate this barrier or modifying it to allow drug transit.
2. Overcoming Hypoxia: Hypoxia triggers the activation of several genes leading to cell survival and chemoresistance. Oxygen-based therapies, the creation of hypoxia-activated prodrugs, and the inhibition of hypoxia-inducible factors are some approaches being explored.
3. Novel Drug Therapies: Researchers are looking into novel drug therapies, including targeted therapies (aimed at specific molecular alterations in cancer cells), immunotherapies (designed to stimulate the body's immune system to fight cancer), and personalized treatments based on each patient's genetic profile.
4. Drug Delivery Systems: New delivery approaches like nanoparticle-based systems, liposomes, micelles, etc., are being developed to enhance drug delivery efficiency and specificity.
5. Combination Therapies: Combination of chemotherapy with other treatments like radiotherapy, targeted therapy, immunotherapy, etc., has shown promise in surmounting resistance.
While advancements in these areas offer hope, much work still lies ahead in the quest to conquer chemoresistance in pancreatic cancer. |
求助已关闭
30